Published in Hepatology on October 01, 2002
Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst (2012) 3.69
Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol (2009) 1.81
Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade--results of an explorative CGH meta-analysis. Br J Cancer (2005) 1.64
Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis (2015) 1.51
Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol (2006) 1.31
Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J Virol (2005) 1.22
Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer (2007) 1.11
R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol (2006) 1.02
Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest. World J Gastroenterol (2007) 0.96
COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs. Front Oncol (2013) 0.94
Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2. World J Gastroenterol (2005) 0.90
E-N-cadherin heterodimers define novel adherens junctions connecting endoderm-derived cells. J Cell Biol (2011) 0.89
Cyclo-oxygenase 2 expression impairs serum-withdrawal-induced apoptosis in liver cells. Biochem J (2006) 0.86
Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma. MedGenMed (2007) 0.85
Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States. Dig Dis Sci (2006) 0.85
Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway. Acta Pharmacol Sin (2009) 0.83
Cyclooxygenase-2 is a target of microRNA-16 in human hepatoma cells. PLoS One (2012) 0.83
Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma. World J Gastroenterol (2011) 0.83
Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. Oncotarget (2014) 0.82
Celecoxib enhances the detoxification of diethylnitrosamine in rat liver cancer. World J Gastroenterol (2009) 0.80
Betulinic acid exerts anti-hepatitis C virus activity via the suppression of NF-κB- and MAPK-ERK1/2-mediated COX-2 expression. Br J Pharmacol (2015) 0.79
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. PLoS One (2013) 0.79
Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Res (2007) 0.79
Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells. Oral Maxillofac Surg (2010) 0.79
ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest. Cancer Lett (2009) 0.79
[Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology]. Pathologe (2007) 0.77
Cyclooxygenase-2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells. J Cancer Res Clin Oncol (2005) 0.77
NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project. Cancer Prev Res (Phila) (2015) 0.77
Pattern of apoptosis by NS398, a selective COX-2 inhibitor, in hepatocellular carcinoma cell lines. Cancer Res Treat (2005) 0.76
Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life (2014) 0.75
Effects of transforming growth factor-beta in the development of inflammatory pseudotumour-like lesions in a murine model. Int J Exp Pathol (2006) 0.75
Binding of Cu(II) complexes of oxicam NSAIDs to alternating AT and homopolymeric AT sequences: differential response to variation in backbone structure. J Biol Inorg Chem (2012) 0.75
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet (2006) 4.43
The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol (2012) 4.30
Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer (2006) 3.16
Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe (2011) 3.05
MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology (2008) 3.00
Most pancreatic cancer resections are R1 resections. Ann Surg Oncol (2008) 2.79
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A (2004) 2.54
Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov (2013) 2.32
Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res (2011) 2.08
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology (2006) 2.05
Exonuclease-1 deletion impairs DNA damage signaling and prolongs lifespan of telomere-dysfunctional mice. Cell (2007) 1.96
Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development. RNA Biol (2012) 1.90
A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell (2013) 1.86
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol (2010) 1.85
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res (2006) 1.82
Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med (2010) 1.80
Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29. Lab Invest (2012) 1.75
K25 (K25irs1), K26 (K25irs2), K27 (K25irs3), and K28 (K25irs4) represent the type I inner root sheath keratins of the human hair follicle. J Invest Dermatol (2006) 1.72
Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis. Hepatology (2008) 1.68
Hepatic NF-kappa B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proc Natl Acad Sci U S A (2008) 1.64
Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation. Gastroenterology (2012) 1.63
Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology (2008) 1.62
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology (2013) 1.58
Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology (2011) 1.57
Quality management and accreditation of research tissue banks: experience of the National Center for Tumor Diseases (NCT) Heidelberg. Virchows Arch (2010) 1.55
Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother (2013) 1.53
Methanobactin reverses acute liver failure in a rat model of Wilson disease. J Clin Invest (2016) 1.52
Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res (2004) 1.50
Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology (2007) 1.48
High salt intake causes adverse fetal programming--vascular effects beyond blood pressure. Nephrol Dial Transplant (2012) 1.46
EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch (2010) 1.45
Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest (2003) 1.45
Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol (2006) 1.45
The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch (2010) 1.44
Iron metabolism and the role of HFE gene polymorphisms in Wilson disease. Liver Int (2011) 1.44
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer (2010) 1.42
Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction. PLoS One (2011) 1.42
Occult cytomegalovirus cholangitis as a potential cause of cholestatic complications after orthotopic liver transplantation? A study of cytomegalovirus DNA in bile. Liver Transpl (2013) 1.42
Noncompaction myocardium in association with type Ib glycogen storage disease. Pathol Res Pract (2012) 1.41
Resistance of keratinocytes to TGFbeta-mediated growth restriction and apoptosis induction accelerates re-epithelialization in skin wounds. J Cell Sci (2002) 1.41
Regulation of DMBT1 via NOD2 and TLR4 in intestinal epithelial cells modulates bacterial recognition and invasion. J Immunol (2007) 1.40
Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res (2011) 1.40
Serum versus intrahepatic HCV RNA and liver histology. Hepatology (2002) 1.39
Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. J Mol Diagn (2013) 1.37
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch (2012) 1.37
p53 deletion impairs clearance of chromosomal-instable stem cells in aging telomere-dysfunctional mice. Nat Genet (2009) 1.33
Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia (2008) 1.33
Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP. Dev Biol (2012) 1.32
Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. Gastroenterology (2007) 1.32
Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. Cancer Res (2007) 1.31
Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology (2008) 1.30
Lipid droplet-associated PAT-proteins show frequent and differential expression in neoplastic steatogenesis. Mod Pathol (2010) 1.29
Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology (2012) 1.29
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol (2012) 1.28
S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology (2009) 1.28
Liver cancer biopsy--back to the future?! Hepatology (2015) 1.26
Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1). Hepatology (2013) 1.26
Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology (2010) 1.26
Gene network dynamics controlling keratinocyte migration. Mol Syst Biol (2008) 1.26
Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology (2004) 1.24
Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res (2009) 1.23
Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol (2006) 1.22
Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology (2003) 1.22
Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. Mol Cell (2012) 1.19
Targeting of the transcription factor STAT4 by antisense phosphorothioate oligonucleotides suppresses collagen-induced arthritis. J Immunol (2007) 1.18
Hepatic granulomas: histological and molecular pathological approach to differential diagnosis--a study of 442 cases. Liver Int (2008) 1.18
DMBT1 confers mucosal protection in vivo and a deletion variant is associated with Crohn's disease. Gastroenterology (2007) 1.18
Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia (2007) 1.17
Invasive ductal breast cancer within a malignant phyllodes tumor: case report and assessment of clonality. Hum Pathol (2009) 1.17
Danger signaling protein HMGB1 induces a distinct form of cell death accompanied by formation of giant mitochondria. Cancer Res (2010) 1.16
Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology (2012) 1.16
Early undifferentiated pancreatic carcinoma with osteoclastlike giant cells: direct evidence for ductal evolution. Am J Surg Pathol (2007) 1.14
The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun (2009) 1.14
Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors. J Clin Invest (2011) 1.14
Elevated expression of c-kit in small venous malformations of blue rubber bleb nevus syndrome. Rare Tumors (2010) 1.13
Pathology of the large intestine in patients with vascular type Ehlers-Danlos syndrome. Virchows Arch (2007) 1.12
Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer (2011) 1.12
Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology (2009) 1.12
Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol (2010) 1.12
Body mass index and microsatellite instability in colorectal cancer: a population-based study. Cancer Epidemiol Biomarkers Prev (2013) 1.12
Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol (2011) 1.11
Transcriptional activation of the beta-catenin gene at the invasion front of colorectal liver metastases. J Pathol (2009) 1.10
ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology (2014) 1.10
Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology (2009) 1.09